Eckert & Ziegler's Market Position and Growth Potential

Eckert & Ziegler SE (EUZ) has been highlighted as a strategic BUY by NuWays AG, with a 12-month target price set at EUR 21.50. This comes amid growing interest in the radiopharma market, driven by recent acquisitions in the sector. Despite trading near its 52-week low, EUZ's foundational strengths in independent isotope supply and specialized manufacturing position it well for future growth.

The company distinguishes itself by partnering with drug developers without competing against them. This strategy can be advantageous as it ensures that EUZ remains a preferred supplier. Current market dynamics reveal significant valuation gaps, presenting a potentially lucrative investment opportunity.

Furthermore, EUZ's robust manufacturing capabilities have proven vital, especially when external manufacturing shortcomings have delayed approvals for other companies. With CDMO sales nearly doubling, EUZ's ability to consistently deliver high-quality products bolsters its market position.